SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Rule.
We are proud of SNBL’s long history of excellence and leadership across our multiple product and service offerings; but more importantly, we benchmark our true success by what we achieve for our customers today and what we do to enable a better future for patients and their families tomorrow.Read More
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. With its multiple worldwide facilities and countless skilled and experienced scientists and technicians, SNBL Group works together in providing a full range of drug development services.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
With the SOT Annual Meeting just around the corner, we are pleased to present SNBL’s final abstract preview. Aiko Sakai, colleague and Unit Supervisor from SNBL DSR (Kagoshima, Japan), is scheduled to present a poster that reviews the effects of specific study procedures on IL-6 levels. At SNBL, we operate and collaborate across our worldwide facilities to provide a full range of drug development services to best meet our clients’ requirements. Ask us how we can support your needs.Read More
Don’t miss our latest SOT 2016 abstract preview. Megumi Arako Bailey, SNBL USA Research Associate Supervisor, is scheduled to present her poster on the topic of NHP infant ECG and echocardiography during the upcoming Meeting, March 16th at 1:15 pm. Stop by the Booth #1409 during SOT to visit with the SNBL Team.Read More
In an effort to garner a better understanding of the pathogenesis and treatment options of metabolic disorders in humans, Narine Lalayeva, SNBL USA Study Director, is scheduled to present a poster that reviews the results of a 52-week study of a long-term high sugar/high fat diet effects on cynomolgus monkeys at the upcoming Society of Toxicology’s 55th Annual Meeting.Read More